Skip to content

Effect of perioperative dietary restriction strategy on intestinal IgA+ B cells in patients with colorectal cancer

Effect of perioperative dietary restriction strategy on intestinal IgA+ B cells in patients with colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062524
Enrollment
Unknown
Registered
2022-08-10
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

experimental group:fasting-mimicking diet
control group:none

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~ 80 years old; 2. Those diagnosed with colorectal cancer by preoperative pathology or colonoscopy; 3. Patients undergoing radical colorectal cancer resection; 4. ASA grade I-III grade; 5. BMI index >= 20; 6. Initial patients have not received any treatment for bowel cancer except neoadjuvant chemotherapy; 7. No evidence of distant metastasis before surgery; 8. Willing to participate in the research of the subject and agree to follow up regularly.

Exclusion criteria

Exclusion criteria: 1. Patients with relapsed colorectal cancer who are going to undergo surgery and re-excision; 2. Accompanied by other malignant tumors; 3. BMI < 20 kg/m^2; 4. History of systemic metabolism such as diabetes; 5. Have a history of immunotherapy before surgery; 6. Combined with clinically significant cardiopulmonary dysfunction, brain disease, renal or hepatic dysfunction; 7. Combined with diseases of the immune system or hematopoietic system; 8. Patients with unresectable tumor burden or distant metastasis who intend to undergo palliative surgery; 9. Patients with gastroesophageal reflux disease, difficulty swallowing, intestinal obstruction; 10. Patients who refuse to participate in the study or cannot receive follow-up.

Design outcomes

Primary

MeasureTime frame
IgA+ B cells;

Secondary

MeasureTime frame
IgA;Length of stay;Frail score;Clavien-dindo score;IgA+ B cells;

Countries

China

Contacts

Public ContactChanghong Miao

Zhongshan Hospital, Fudan University

miaochh@aliyun.com+86 13681975062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026